FGF-23 and cardiovascular disease: review of literature

Jasveen Batra, Rupinder Singh Buttar, Pardeep Kaur, Jacqueline Kreimerman, Michal L. Melamed

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

Original languageEnglish (US)
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
DOIs
Publication statusAccepted/In press - Sep 20 2016

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this